Lundbeck earnings plummet 28% on generics; Richter eyes 3% growth for 2013;

@FiercePharma: Here's one way for pharma to boost earnings: Cut tax rates. Story | Follow @FiercePharma

@EricPFierce: Would your plant receive an A or an F under FDA Woodcock's suggestion of letter grades for quality? More from FiercePharmaManufacturing | Follow @EricPFierce

@AlisonBFierce: GBI Research forecasts that the global pediatric vaccines market will hit $24.3 billion by 2017. More | Follow @AlisonBFierce

> Denmark's Lundbeck continued the pharma trend of flat revenues and double-digit declines in profits, with a 28% earnings drop for the fourth quarter. Report

> Hungarian drugmaker Richter sees sales rising 3% this year, on top of 2.8% growth in 2012, to €1.13 billion ($1.53 billion). Report

> Over-the-counter drugmaker Perrigo snapped up the pet-care company Velcera for $160 million to expand its presence in animal health. Report

> GlaxoSmithKline ($GSK) CEO Andrew Witty said he was thrilled with employees' reaction to the company's new Philadelphia offices, which use a radically different, open design. Report

> U.S. pharmacy chains are reaping higher sales from the fast-breaking flu season. Report

Biotech News

 @FierceBiotech: From Biotech, pharma warming up to Facebook. Article | Follow @FierceBiotech

@JohnCFierce: 7 pharmas join hands to create a new discovery platform--€196M: Report | Follow @JohnCFierce

@RyanMFierce: The Swiss biotech Addex is downsizing its Geneva operation after cuts last year. No details on jobs. Release | Follow @RyanMFierce

> Elan fails to inspire analysts with deal-making plans for $3.25B. Report

> Ticktock: Lilly scraps RA program as another PhIII drug disappoints. News

Medical Device News

 @FierceMedDev: True Diagnostics revs up EU prostate cancer Dx launch. Story | Follow @FierceMedDev

 @MarkHFierce: Minnesota's legislative delegation is pursuing a new repeal effort for the 2.3% medical device tax. News | Follow @MarkHFierce

 @DamianFierce: A new brain-stimulation method could make a major difference for depression sufferers, according to a study. More | Follow @DamianFierce

> Smith & Nephew watches profits slip as it reorganizes. Report

> Stryker crushes Zimmer with $70M patent violation verdict. Story

Pharma Manufacturing News

> Specialized manufacturing technology punches ticket to Protalix's value. Report

> China sends 7 to prison for producing toxic capsules. Story

> Meds from foreign plants complicate counterfeit search. More

> GSK to squeeze manufacturing in Europe but U.K. spared. Article

Vaccines News

> Global health funding slows amid financial concerns. Report

> Parents supportive of vaccinating boys for HPV. Item

> Gates-backed researchers explore pain-free vaccine technology. Article

> Merck, GSK partner with GAVI to provide low-cost HPV vaccine. News

> Despite setback, TB vaccine study is a step in the right direction. More

And Finally... Men earning less than their wives use erectile dysfunction drugs more often, a study found. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.